H. Lundbeck A/S
Clinical trials sponsored by H. Lundbeck A/S, explained in plain language.
A pharmaceutical company focused on brain diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for teens with chronic migraines? Results expected Sep 2026 (estimated)
- New hope for rare hormone disorder: drug targets Out-of-Control cortisol Results expected Sep 2026 (estimated)
- New infusion drug hopes to tame rare hormone disorder Results expected Sep 2026 (estimated)
- Can a new drug play well with others? a trial puts it to the test Results expected Nov 2026 (estimated)
- New narcolepsy drug enters first human safety tests Results expected Feb 2027 (estimated)
-
New drug aims to calm swollen eyes in thyroid disease patients
Disease control OngoingThis study tests an experimental drug called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the drug can reduce eye bulging over 24 weeks. Participants receive the drug …
Phase 1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
Hope for rare brain disease: new drug trial targets MSA progression
Disease control OngoingThis Phase 3 trial tests an experimental drug called amlenetug in 401 people with multiple system atrophy (MSA), a rare and serious brain disorder. The goal is to see if the drug can slow the worsening of symptoms and improve survival. Participants receive either the drug or a pl…
Phase 3 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Hope for rare brain disease: new drug aims to slow MSA
Disease control OngoingThis study tests an experimental drug called Lu AF82422 in 64 people with multiple system atrophy (MSA), a rare and serious brain disease. The goal is to see if the drug can slow down the worsening of symptoms like movement problems and daily living difficulties. Participants rec…
Phase 2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Scientists watch MSA progress in real time to unlock clues
Knowledge-focused OngoingThis study follows 90 people with Multiple System Atrophy (MSA), a rare brain disease, for 12 months. Researchers measure changes in movement, thinking, brain scans, and blood markers to better understand how the disease progresses. The goal is to gather information, not to test …
Sponsor: H. Lundbeck A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC